These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14576660)

  • 41. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enfuvirtide: from basic investigations to current clinical use.
    Joly V; Jidar K; Tatay M; Yeni P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J
    J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
    Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
    HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 48. Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.
    Foy K; Bradley-Springer L; Kempner T; Stevens L; Gahagan L
    J Assoc Nurses AIDS Care; 2005; 16(2):2-12. PubMed ID: 16438121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors].
    Koopmans PP
    Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1726-9. PubMed ID: 14520797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 51. [Enfuvirtide].
    Gerstoft J
    Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Entry inhibitors. Ring-free for a new principle of action].
    Rümmelein N; Jäger H
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 55. Development of HIV fusion inhibitors.
    Schneider SE; Bray BL; Mader CJ; Friedrich PE; Anderson MW; Taylor TS; Boshernitzan N; Niemi TE; Fulcher BC; Whight SR; White JM; Greene RJ; Stoltenberg LE; Lichty M
    J Pept Sci; 2005 Nov; 11(11):744-53. PubMed ID: 16130177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?
    Maggi P; Filotico R; Bonora S; Volpe A; Bellacosa C; Cinori E; de Requena DG; D'Avolio A; Di Perri G
    Clin Drug Investig; 2008; 28(5):305-11. PubMed ID: 18407716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The fusion inhibitor enfuvirtide in recent antiretroviral strategies.
    Makinson A; Reynes J
    Curr Opin HIV AIDS; 2009 Mar; 4(2):150-8. PubMed ID: 19339955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 60. Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
    Glutzer E; Lalezari JP
    J Assoc Nurses AIDS Care; 2005; 16(5):26-34. PubMed ID: 16433107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.